Healthcare / Medical Instruments & SuppliesNasdaqCM
$6.40
+0.52 (+8.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $4.9M · quality 14.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$29M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-412.8%
↓Gross Margin
57.7%
↑Debt/Equity
3.22
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+0.1%
FCF CAGR
—
FCF margin
5.6%
FCF / Net income
-0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $86.5M · net income $-56.7M · FCF $4.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $86.5M | $86.5M | $94.1M | $112.3M | $113.3M | $118.9M | $102.1M | $116.2M | $120.8M | $77.4M | $104.5M | $108.7M | $108.7M | $105.2M | $111.2M | $108.9M | $108.2M | $85.8M |
| Net Income | $-56.7M | $-56.7M | $-12.4M | $-3.4M | $-9.5M | $-288000.00 | $-7.8M | $-4.7M | $-2.9M | $-865000.00 | $-4.3M | $-19.0M | $2.4M | $-1.8M | $2.4M | $3.8M | $19.0M | $7.2M |
| EBITDA | $-46.5M | $-46.5M | $-972000.00 | $8.0M | $944000.00 | — | — | — | — | — | — | — | — | — | $12.0M | $12.7M | $14.1M | — |
| EPS | -12.80 | -12.80 | -2.80 | -0.80 | -2.30 | -0.10 | — | -1.20 | -0.80 | -0.20 | -1.30 | -5.70 | 0.70 | -0.60 | 0.80 | 1.30 | 4.93 | 1.82 |
| Gross Margin | 57.7% | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% | 56.8% | 55.4% | 52.3% | 50.6% | 46.3% | 44.8% | 45.4% | 45.4% | 47.1% | 46.1% | 47.9% | 48.6% |
| Operating Margin | 0.1% | 0.1% | -6.6% | 1.7% | -6.3% | 1.7% | 0.2% | 0.3% | 0.8% | -0.8% | -2.9% | -1.6% | 6.1% | 1.5% | 7.0% | 7.7% | 9.4% | 9.4% |
| Net Margin | -65.5% | -65.5% | -13.2% | -3.0% | -8.4% | -0.2% | -7.6% | -4.0% | -2.4% | -1.1% | -4.1% | -17.5% | 2.2% | -1.7% | 2.1% | 3.5% | 17.6% | 8.4% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 3.22 | 3.22 | 0.70 | 0.59 | 0.75 | 0.54 | 0.60 | 0.57 | 0.66 | 0.11 | 0.16 | 0.21 | 0.17 | 0.21 | 0.12 | 0.17 | 0.20 | — |
| Current Ratio | 1.99 | 1.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $4.9M | $4.9M | $-1.8M | $11.7M | $-438000.00 | $67000.00 | $8.2M | $6.8M | $1.9M | $167000.00 | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | -412.8% | -412.8% | -19.6% | -4.7% | -13.2% | -0.3% | -10.2% | -5.7% | -3.5% | -1.1% | -6.0% | -24.5% | 2.5% | -1.9% | 2.3% | 4.0% | 21.1% | 9.6% |
| Valuation | ||||||||||||||||||
| EV/EBITDA | — | — | — | 30.46 | 175.96 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.07 | 2.07 | 1.47 | 2.82 | 1.61 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -8.1% | -8.1% | -16.1% | -1.0% | — | 16.5% | -12.1% | -3.8% | 56.0% | -25.9% | -3.8% | 0.0% | 3.3% | -5.4% | 2.1% | 0.6% | 26.1% | — |
| EPS Growth | -357.1% | -357.1% | -250.0% | 65.2% | — | — | — | -50.0% | -300.0% | 84.6% | 77.2% | -914.3% | 216.7% | -175.0% | -38.5% | -73.6% | 170.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.80 → -12.80
Residual
+36.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.